Ramipril

證據等級: L5

預測適應症: 10 個

Ramipril: From ACE Inhibitor Therapy (Hypertension) to Pulmonary Hypertension with Unclear Multifactorial Mechanism

One-Sentence Summary

Ramipril (DrugBank DB00178) is a well-established angiotensin-converting enzyme (ACE) inhibitor; specific SAHPRA-registered indication text is not available in this evidence pack because the product is currently not marketed in South Africa. The TxGNN model’s top-ranked prediction is pulmonary hypertension with unclear multifactorial mechanism, but this candidate is currently supported by zero clinical trials and zero publications — the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not available from SAHPRA registry data (product not marketed); as an ACE inhibitor, ramipril’s globally established indications are hypertension, heart failure and cardiovascular risk reduction
Predicted New Indication	Pulmonary hypertension with unclear multifactorial mechanism
TxGNN Prediction Score	99.93%
Evidence Level	L5
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for ramipril is flagged as a data gap in this evidence pack. Based on generally known pharmacology, ramipril is an ACE inhibitor that suppresses the renin-angiotensin-aldosterone system (RAAS), and its efficacy in hypertension and cardiovascular risk reduction is well established.

However, for this specific top-ranked candidate — pulmonary hypertension with unclear multifactorial mechanism (WHO Group 5) — the evidence pack’s own repurposing rationale is explicit: “TxGNN gives a high score but there is no trial or literature support, and the mechanism of this indication itself is not clearly defined, so no concrete pharmacological hypothesis can be established.” In other words, because this WHO Group 5 category is defined by heterogeneous and unclear mechanisms, RAAS inhibition cannot currently be mapped to a specific pathophysiological rationale for this indication.

By contrast, other TxGNN-predicted indications for ramipril in this evidence pack (not detailed further below, since this report follows the top-ranked candidate) have much clearer mechanistic links — for example, malignant renovascular hypertension (RAAS-driven, direct ACEI mechanism) and cerebral artery occlusion (supported by a completed Phase 2 trial and human cohort data). These may warrant separate evaluation if a viable repurposing candidate is the goal (see Conclusion).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Ramipril has 0 SAHPRA registrations in this evidence pack, and market status is recorded as Not Marketed. No product licences, dosage forms, or approved indication text are currently available for South Africa.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: Retrieval of PI-based warnings/contraindications is flagged in this evidence pack as a Blocking data gap (DG001) — this must be resolved before any safety pre-assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (pulmonary hypertension with unclear multifactorial mechanism) has no supporting clinical trials or literature and no established mechanistic hypothesis — evidence level L5. Combined with the product’s Not Marketed status in South Africa (0 registrations) and a Blocking data gap on safety/PI data, there is currently no basis to advance this specific candidate.

To proceed, the following is needed:

TFDA/SAHPRA Professional Information (PI) warnings, precautions and contraindications (DG001, Blocking)
Confirmed mechanism of action via DrugBank API (DG002, High)
Dedicated clinical or preclinical studies of ramipril specifically in WHO Group 5 pulmonary hypertension
If the goal is to identify a viable repurposing candidate for ramipril generally, consider prioritising other predictions in this evidence pack with stronger evidence — notably cerebral artery occlusion (rank 10, evidence level L2, one completed Phase 2 trial plus a human cohort study and multiple animal studies) and malignant renovascular hypertension (rank 3, L4, strong direct RAAS mechanistic link) — over the current top-ranked but evidence-free candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.